Category Archives: 2020

Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 results in Progressive Forms of MS

09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis

New fundraising of EUR 12.3 million

02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million

Positive top-line Phase 2B/3 results for masitinib in progressive forms of MS

20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis

FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancer

08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy